Business Wire

CIVIL-SOCIETY-20

22.3.2020 18:51:13 CET | Business Wire | Press release

Share
Urgent Statement by the Civil 20 to the G20 Virtual Summit on COVID-19: New Realities Require New Priorities

The following is a statement by Civil 20:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200322005022/en/

The events of this year alone, starting with the bushfires in Australia and moving to the outbreak of COVID-19, underscored the ever-growing complexity of our global shared challenges and expose the weaknesses of the current dominant economic system, and how it deepens inequalities between individuals and countries. We ask that G20 leaders recognize our new global reality and reorient this year’s G20 priorities towards building a more resilient global governance.

G20 leaders need to uphold the principles of human rights, civic engagement, and democracy. As the crisis develops, the C20 observes with great alarm the continued deterioration of the situation for many vulnerable groups in different societies. Governments must protect and extend medical care to all people without leaving anyone behind.

The infodemic surrounding the disease is equally fatal to the virus. The C20 stands in solidarity with communities suffering as a result of different governments’ lack of transparency. Governments are accountable in their response to the crisis, and work on empowering local communities and civil society actors in responding to the outbreak.

We can learn from previous public health emergencies the importance of quality care continuum, protection of human rights, anti-discrimination and isolation of people living with the diseases and affected communities. COVID-19 is a sobering reminder that we need to increase investment in what we know works: strong international partnerships, building health care delivery systems that reach everyone, research and development, and an approach to care that prioritizes the most marginalized. The C20 urges that G20 leaders consider the recommendations in the statement on pandemic preparedness released jointly with the Business 20, Labor 20, Think 20, Women 20 and Youth 20.

Another emerging lesson out of this emergency, is that hyper-globalization of our supply chains is making our trade systems extremely vulnerable to shocks. The C20 cautions G20 leaders against the ongoing attempts in trade agreement negotiations to open “health markets” to foreign investors and competition, turning health systems into yet another investment opportunity. We worry that the divide between those who can afford healthcare and those who cannot will be exacerbated.

The C20 warns that inequalities will ensue as a consequence of the outbreak. Labor policies need to be put in place to address the needs of the most vulnerable, who cannot afford to sit at home, and prepare for the expected rise in working poverty, especially in countries with a high informal economy, where women are over-represented.

The world is in need of multilateral coordination of an effective response to the economic crisis that provides adequate fiscal and monetary stimulus, while safeguarding liquidity from misuse by speculative activities. A fairly designed stimulus package should take into account not only the interest of businesses and SMEs, but also households, workers, and the most vulnerable.

A problem with multiple dimensions requires a solution by multiple actors. Members of Civil Society and humanitarian NGOs continue to face tightened financial restrictions due to risk and cost aversion by banks in complying with FATF regulations. Such financial exclusion limits our ability to respond to global emergencies.

We implore the G20 Leaders to take immediate action in responding to the substantial impact on education and the dwindling prospects of ensuring access. The world is entirely unequipped to maintain a promise of “education for all”; particularly in contexts where classrooms can no longer provide a safe environment for learning.

The C20 calls on G20 leaders to expand this year’s G20 priorities to vigilantly respond to the changes in the labor market through expanding social protection systems, ensure digital and eLearning is accessible across, prioritize child online safety, address rising risks to debt sustainability in emerging markets as they face urgent financing needs to improve health systems capacity to respond to the COVID-19 outbreak, including debt relief and attending to their exposure to volatile capital flows.

Civil Society 20 (C20) is one of the eight official Engagement Groups of the G20. It provides a platform of Civil Society Organizations around the world to bring forth a non-government and non-business voice.

*Source: AETOSWire

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye